| Use of Immune Checkpoint Inhibitors in the Treatment of Patients with Cancer and Preexisting Autoimmune Diseases: A Systematic Review of Case Reports N Abdel-Wahab, M Shah, ME Suarez-Almazor Arthritis Rheum (Suppl) 68 (10), S1342, 2016 | 570 | 2016 |
| Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. N Abdel-Wahab, M Shah, ME Suarez-Almazor PLoS One 11 (7), e0160221, 2016 | 534 | 2016 |
| Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity Y Hailemichael, DH Johnson, N Abdel-Wahab, WC Foo, SE Bentebibel, ... Cancer Cell 40 (5), 509-523. e6, 2022 | 326 | 2022 |
| Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature N Abdel-Wahab, H Safa, A Abudayyeh, DH Johnson, VA Trinh, ... Journal for immunotherapy of cancer 7 (1), 106, 2019 | 316 | 2019 |
| Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience O Mamlouk, U Selamet, S Machado, M Abdelrahim, WF Glass, ... Journal for immunotherapy of cancer 7 (1), 2, 2019 | 298 | 2019 |
| Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature H Safa, DH Johnson, VA Trinh, TE Rodgers, H Lin, ME Suarez-Almazor, ... Journal for immunotherapy of cancer 7 (1), 319, 2019 | 296 | 2019 |
| Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis DH Johnson, CM Zobniw, VA Trinh, J Ma, RL Bassett Jr, N Abdel-Wahab, ... Journal for immunotherapy of cancer 6 (1), 103, 2018 | 193 | 2018 |
| A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant N Murakami, P Mulvaney, M Danesh, A Abudayyeh, A Diab, ... Kidney international 100 (1), 196-205, 2021 | 192 | 2021 |
| Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis N Abdel-Wahab, S Talathi, MA Lopez-Olivo, ME Suarez-Almazor Lupus 27 (4), 572-583, 2018 | 169 | 2018 |
| Systematic review of case reports of antiphospholipid syndrome following infection N Abdel-Wahab, MA Lopez-Olivo, GP Pinto-Patarroyo, ... Lupus 25 (14), 1520-1531, 2016 | 165 | 2016 |
| Immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. ME Suarez‐Almazor, ST Kim, N Abdel‐Wahab, A Diab Arthritis & rheumatology 69 (4), 2017 | 149 | 2017 |
| Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors J Aldrich, X Pundole, S Tummala, N Palaskas, CR Andersen, M Shoukier, ... Arthritis & Rheumatology 73 (5), 866-874, 2021 | 126 | 2021 |
| Myositis as an adverse event of immune checkpoint blockade for cancer therapy M Shah, JH Tayar, N Abdel-Wahab, ME Suarez-Almazor Seminars in arthritis and rheumatism 48 (4), 736-740, 2019 | 120 | 2019 |
| Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events F Fa'ak, M Buni, A Falohun, H Lu, J Song, DH Johnson, CM Zobniw, ... Journal for immunotherapy of cancer 11 (6), e006814, 2023 | 101 | 2023 |
| Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy ST Kim, Y Chu, M Misoi, ME Suarez-Almazor, JH Tayar, H Lu, M Buni, ... Nature communications 13 (1), 1970, 2022 | 101 | 2022 |
| Adverse events in cancer immunotherapy N Abdel-Wahab, A Alshawa, ME Suarez-Almazor Immunotherapy, 155-174, 2017 | 89 | 2017 |
| Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy N Abdel-Wahab, ME Suarez-Almazor Rheumatology 58 (Supplement_7), vii40-vii48, 2019 | 77 | 2019 |
| Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis AR Bass, N Abdel-Wahab, PD Reid, JA Sparks, C Calabrese, ... Annals of the rheumatic diseases 82 (7), 920-926, 2023 | 71 | 2023 |
| Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors N Abdel-Wahab, A Diab, RK Yu, A Futreal, LA Criswell, JH Tayar, R Dadu, ... Cancer Immunology, Immunotherapy 70 (7), 1939-1949, 2021 | 64 | 2021 |
| Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis JS Lin, O Mamlouk, U Selamet, A Tchakarov, WF Glass, RA Sheth, ... Oncoimmunology 10 (1), 1877415, 2021 | 63 | 2021 |
